Evidence exists for epigenetic contributions to hypertension in animal models and identified different targets, namely: i) the upregulation of the angiotensin receptor gene (AT1b) in the rat adrenal gland by hypomethylation during the first week of life [29]; ii) an epigenetic regulation of the connective-tissue growth factor gene (CTFG) which involves the histone disruptor of telomeric silencing-1 (Dot1) and has a role in blood vessel remodeling and renal fibrosis [30,31]; iii) the enzyme chromodomain-helicase-DNA-binding protein 2 (CHD2) [32]. This evidence concerns the gene CCN2 and hypertensive disorder.